Fetching financial data...

360investing

★ Watchlist

Alnylam Pharmaceuticals, Inc.

NASDAQ · Healthcare
Alnylam Pharmaceuticals, Inc.
ALNY · Biotechnology
$296.19
▲ 0.08 (0.03%)
Data cached · refreshes every 10 min
Mr. Market is currently offering Alnylam Pharmaceuticals, Inc. at $296.19.
The business passes only 2 of 6 of Graham's defensive criteria — well below his required standard.
Overall Grade
C
Defensive
B
Enterprising
Profitability B
Gross Profit Margin 81.6%
Operating Margin 13.5%
Net Income Margin 8.4%
Fin. Health B
Years to Pay Off Debt 4.1 yrs
Working Capital vs Long-Term Debt $1.6B
Working Capital $2.6B
Valuation F
Margin of Safety 0.0%
Price-to-Book 50.08x
Cash Flow A
Free Cash Flow $465M
CapEx % of Net Income 18.7%
Owner Earnings $428M
2/6
Graham Score
Speculative
Defensive — Graham's strict criteria (P/B, P/E, dividends, stability)  ·  Enterprising — Profitability & cash flow focused, accepts higher valuations for quality
Metric Explanations
What each dimension measures and where the thresholds come from.
Gross Profit Margin
Revenue minus cost of goods sold. Graham's ≥40% threshold identifies businesses with durable pricing power. Note: software and financial companies naturally exceed this; retailers and manufacturers rarely reach it due to their cost structures.
Operating Margin
Profit after operating costs before interest and taxes. A consistent ≥15% operating margin signals a business with real competitive advantages. Capital-intensive industries (airlines, auto, commodities) rarely hit this threshold due to their structural cost base — compare within industry for context.
Net Income Margin
Bottom-line profit as a percentage of revenue. The ≥20% target reflects Buffett's preference for highly profitable businesses. Financial engineering (buybacks, tax optimisation) can inflate this temporarily — look for consistency across multiple years rather than a single strong result.
Years to Pay Off Debt
Total Debt ÷ Net Income. Lower = stronger balance sheet. Important caveat: utilities, telecoms, REITs, and infrastructure companies carry large structural debt by design — their bond-like cash flows service it comfortably at ratios that would alarm Graham. Compare within sector.
Working Capital vs Long-Term Debt
Working Capital minus Long-Term Debt. Negative results are common and expected in capital-return-focused businesses like Apple, Domino's, and McDonald's — where aggressive buybacks and dividends intentionally reduce book equity. This does not indicate financial distress in high-FCF businesses.
Working Capital
Current Assets minus Current Liabilities. Negative working capital can be a deliberate efficiency strategy in businesses that collect cash before paying suppliers (retailers, fast food franchises, subscription businesses). Assess alongside free cash flow generation for full context.
Margin of Safety
How far below the Graham Number the stock trades. Graham required a 33% discount as a buffer against analytical error. However, the Graham Number itself assumes 1960s-era P/E and P/B norms — for modern asset-light businesses it often understates true intrinsic value, making 0% MoS appear misleadingly bad.
Price-to-Book
Market price vs book value per share. Rarely below 1.5x for quality businesses today. Intangible assets (brand, software, patents) don't appear on the balance sheet under accounting rules, making P/B artificially high for asset-light companies. Negative P/B indicates book equity has been reduced by buybacks — common in highly profitable capital-return businesses.
Free Cash Flow
Operating cash flow minus capital expenditures. Buffett's most important metric — cash a business actually generates for its owners after maintaining and growing its asset base. Consistently positive FCF is one of the strongest indicators of a durable, well-run business regardless of accounting profits.
CapEx % of Net Income
Capital expenditure as a share of net income. Low CapEx signals a capital-light business that doesn't need heavy reinvestment to sustain earnings — Buffett's ideal. High CapEx is structurally necessary in manufacturing, airlines, telecoms, and semiconductors. For these industries, a high reading reflects the business model, not poor management.
Owner Earnings
Net Income + Depreciation & Amortisation − Capital Expenditures. Buffett's preferred measure of a company's true annual earning power — what could theoretically be distributed to owners without impairing the business. More reliable than reported EPS because it accounts for the capital cost of maintaining the business.
Market Data
Market Cap $39.5B
Enterprise Value $39.5B
P/E (TTM) 74.61
Dividend Yield N/A
Exchange NASDAQ
Key Margins
Gross Profit 81.6%
Operating Margin 13.5%
Net Margin 8.4%
Company Info
Sector Healthcare
Industry Biotechnology
Employees 2500
Country United States
Visit website
📖
Full Graham Analysis

Mr. Market is currently offering Alnylam Pharmaceuticals, Inc. at $296.19.

The business passes only 2 of 6 of Graham's defensive criteria — well below his required standard.

At $296.19, the stock trades at a 1582% premium to its Graham Number of $17.61. Graham would consider this price speculative.

There is no margin of safety at the current price. Graham would advise patience and waiting for a better entry point.

Negative NCAV — liabilities exceed current assets. Common in capital-return businesses (buybacks, debt-funded dividends) and capital-intensive industries. Not automatically a warning sign..

Conclusion: By Graham's standards, this stock is speculative at its current price. The intelligent investor would look elsewhere or wait.

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Showing Key Metrics
Income Highlights
Metric 2025 2024 2023 2022
Gross Profit % 81.6% ▼ 85.6% 83.0% 83.7%
Operating Margin % 13.5% ▲ -7.9% -15.4% -75.7%
Net Income % 8.4% ▲ -12.4% -24.1% -109.0%
Diluted EPS 2.33 ▲ -2.18 -3.52 -9.30
Balance Sheet Highlights
Metric 2025 2024 2023 2022 2021
Total Assets $5.0B $4.2B $3.8B $3.5B N/A
Total Debt $1.3B ↓ $1.3B $1.3B $1.3B N/A
Working Capital $2.6B ▲ $2.1B $2.0B $1.9B N/A
Years to Pay Debt 4.07 -4.66 -2.97 -1.17 N/A
Cash Flow Highlights
Metric 2025 2024 2023 2022 2021
Free Cash Flow $465M ▲ -$43M $42M -$613M N/A
Owner Earnings $428M -$187M -$324M -$1.0B N/A
CapEx % of Net Income 18.7% N/A N/A N/A N/A
These metrics estimate what Alnylam Pharmaceuticals, Inc. is worth based on its fundamentals — independent of what the market currently prices it at. Graham's Fair Value and NCAV are conservative floors rooted in 1930s–60s principles. EPV assumes zero growth. None are price targets — they are reference points for judging whether the current price offers a margin of safety.
Graham's Fair Value
$17.61
Margin of Safety
0%
Market Cap ÷ Company Value
2.28
P/B Ratio
50.08
Warren's Owner Earnings
$428M
Latest fiscal year
Graham's 7 Criteria
Defensive Investor Checklist
2/6 — Speculative Investor
✅ Adequate Size
$3.7B
vs > $1.5B revenue
✅ Strong Financial Condition
2.76x
vs Current Ratio > 2.0x
❌ Earnings Stability
3 loss years (4 yrs data)
vs No negative EPS years
❌ Dividend Record
No dividend
vs Uninterrupted dividends
❌ Moderate P/E Ratio
74.6x
vs P/E ≤ 15.0x
❌ Moderate Price-to-Book
50.08x P/B (P/E×P/B: 3736.5)
vs P/B ≤ 1.5x | P/E × P/B ≤ 22.5
Graham's 7 Criteria — Explained
What each criterion measures and why it may or may not apply to modern businesses.
✅ Adequate Size — $3.7B vs > $1.5B revenue
Graham required companies large enough to withstand economic downturns. This threshold ($1.5B) is inflation-adjusted from Graham's original $100M — virtually all S&P 500 companies pass this today.
"The minimum size of an enterprise should be not less than $100 million of annual sales."
✅ Strong Financial Condition — 2.76x vs Current Ratio > 2.0x
Current assets must be at least twice current liabilities. Note: highly profitable companies (Apple, Domino's) often run negative or low working capital deliberately — they collect cash fast and stretch payables. A failing score here is not always a warning sign.
"For industrial companies, current assets should be at least twice current liabilities."
❌ Earnings Stability — 3 loss years (4 yrs data) vs No negative EPS years
Graham required uninterrupted positive earnings. Any loss year is a red flag for defensive investors. Growth companies and cyclicals may show occasional losses during investment cycles or downturns without being fundamentally unsound.
"The company should have shown no deficit in the past ten years."
❌ Dividend Record — No dividend vs Uninterrupted dividends
Graham valued dividends as evidence of financial discipline and shareholder alignment. Many excellent modern businesses (Alphabet, Amazon, Berkshire Hathaway) pay no dividend, preferring to reinvest cash at high rates of return. Failing this criterion does not indicate a poor business — it may indicate a high-growth one.
"Some current dividend payments — for at least the past 20 years."
❌ Moderate P/E Ratio — 74.6x vs P/E ≤ 15.0x
Graham's 15x P/E threshold was calibrated to 1960s market averages when interest rates were higher. Today's lower rate environment structurally supports higher multiples — the S&P 500 long-run average P/E is now closer to 20–25x. A stock trading at 20x is not automatically speculative in the modern context.
"The price-earnings ratio should be no more than 15 times average earnings."
❌ Moderate Price-to-Book — 50.08x P/B (P/E×P/B: 3736.5) vs P/B ≤ 1.5x | P/E × P/B ≤ 22.5
Graham's 1.5x P/B threshold made sense when most company value was tangible. Today, intangible assets — brand, software, patents, network effects — rarely appear on the balance sheet. A high P/B in tech, pharma, or consumer brands often reflects intangible value, not overvaluation. P/FCF or EV/EBITDA are more reliable for asset-light businesses.
"The price should not be more than 1½ times book value. P/E × P/B ≤ 22.5."
Net Current Asset Value
$-0.95
Negative NCAV — liabilities exceed current assets. Common in capital-return businesses (buybacks, debt-funded dividends) and capital-intensive industries. Not automatically a warning sign.
"Buy at two-thirds of net current assets." — Graham
Earnings Power Value
$41.76
Per share, no-growth floor. Compare to current price.
Cash Flow Analysis
Metric 2025 2024 2023 2022 2021
Capital Expenditure % of Net Income 18.7% N/A N/A N/A N/A
Repurchase of Capital Stock N/A N/A N/A N/A N/A
Free Cash Flow $465M ▲ -$43M ▼ $42M ▲ -$613M • N/A •
Warren's Owner Earnings $428M -$187M -$324M -$1.0B N/A
Peers & Industry Comparison
Biotechnology — Auto-detected peers
Company Price Market Cap P/E Gross Margin Net Margin Revenue
ALNY $296.19 $39.5B 74.61 81.6% 8.4% $3.7B
AMGN
Amgen Inc.		 $322.25 $173.9B 22.4 71.4% 21.0% $37.2B
GILD
Gilead Sciences, Inc.		 $132.46 $164.4B 19.5 78.8% 28.9% $29.4B
BIIB
Biogen Inc.		 $187.34 $27.7B 20.1 78.7% 13.8% $9.9B
REGN
Regeneron Pharmaceuticals, Inc.		 $708.90 $74.3B 17.3 43.9% 29.6% $14.9B
VRTX
Vertex Pharmaceuticals Incorpor		 $428.53 $109.0B 28.0 53.7% 32.9% $12.0B
"The management of a business is its most important single factor — more important than market position, patents, or financial structure."
— Benjamin Graham
Capital Allocation & Alignment
Insider Ownership
0.19%
Low — management has little skin in the game
Return on Equity (ROE)
39.8%
Excellent — management generates strong returns on equity
Return on Assets (ROA)
6.3%
Strong — management uses assets efficiently
Debt Trend YoY
-1.4% YoY
Debt is declining — management is deleveraging
Leadership Team
Yvonne Greenstreet ,
CEO & Director
Age 62
Pay: $4,991,720
1.591% of net income
Phillip Sharp Ph.
Co-Founder, Member of the Scientific Advisory Board
Age 80
Pay: $52,930
0.017% of net income
Jeffrey Poulton
CFO & Executive VP
Age 57
Pay: $1,697,100
0.541% of net income
Top Institutional Holders
Institution % Owned Shares
Capital World Investors 12.22% 16,301,772
FMR, LLC 11.92% 15,902,149
Vanguard Group Inc 10.16% 13,553,932
Blackrock Inc. 7.80% 10,400,874
Capital Research Global Investors 5.08% 6,779,708
JPMORGAN CHASE & CO 3.54% 4,719,999
State Street Corporation 2.42% 3,228,956
Geode Capital Management, LLC 1.99% 2,650,722
Risk Analysis
Beta (Market Risk)
0.30
Low volatility — more stable than the market
Short Interest
5.0% of float
Moderate short interest
Debt-to-Equity
2.76x
High leverage — significant financial risk
Current Ratio
3.13x
Strong liquidity — Graham approved
52-Week Price Range
Low: $245.96 Current: $296.19 High: $495.55
Currently at 20% of 52-week range

Alnylam Pharmaceuticals, Inc. (ALNY) fundamental analysis — Overall grade C based on profitability, financial health, valuation and cash flow. Graham's Fair Value: $17.61. Margin of safety: 0%. Gross profit margin: 81.6%. Operating margin: 13.5%. Net margin: 8.4%. Market cap: $39.5B. Sector: Healthcare. Industry: Biotechnology. Analysis powered by 360investing — free fundamental stock analysis based on Benjamin Graham and Warren Buffett principles.

Disclaimer: 360investing is provided for informational and educational purposes only and does not constitute financial, investment, legal, or tax advice. All data is sourced from public third-party providers and may be delayed, inaccurate, or incomplete. Past performance is not indicative of future results. Analysis, scores, and valuations are algorithmic and do not represent professional investment recommendations. Always conduct your own due diligence and consult a qualified financial adviser before making any investment decision. Use of this tool constitutes acceptance that 360investing and its operators bear no liability for decisions made based on information presented here.

Data Sources & Methodology Privacy Policy